ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
APOE ε4 linked effects on clinical features and neuropathology in dementia with Lewy bodies.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Effect of genetic factors on [European journal of nuclear medicine and molecular imaging · 2026Article
- APOE ε4 linked effects on clinical features and neuropathology in dementia with Lewy bodies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Towards optimizing the diagnosis of Lewy body dementia: Lessons from the NACC.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionApolipoprotein E (APOE) ε4 is a strong genetic risk factor for Alzheimer's disease (AD) neuropathologic changes, but its contribution to clinical features and pathology in dementia with Lewy bodies (DLB) is less clear.
methodsUsing the National Alzheimer Coordinating Center dataset, we investigated APOE ε4-associated effects on DLB core clinical features and neuropathology.
resultsIn analyses of APOE ε4 carriers, dosage, and genetic risk score, APOE ε4 was associated with lower odds of fluctuating cognition and parkinsonism and higher odds of visual hallucinations. APOE ε4 was associated with greater neocortical Lewy body pathology, partially mediated by AD co-pathology. The severity of fluctuating cognition was associated with Lewy body pathology stage after controlling for AD co-pathology. Visual hallucinations were associated with both Lewy body and AD pathologies. DISCUSSION: Core clinical features of DLB are sensitive to APOE haplotype. Targeting APOE biology may elucidate DLB pathogenesis and inform therapeutic development. HIGHLIGHTS: Core clinical features of dementia with Lewy bodies were sensitive to apolipoprotein E (APOE) haplotype. APOE ε4 was associated with a higher likelihood of hallucinations yet a lower likelihood of cognitive fluctuations. APOE ε4 was associated with greater severity of Lewy body pathology, partially mediated by Alzheimer's disease (AD) co-pathology. Whereas fluctuating cognition was primarily linked to Lewy body pathology, visual hallucinations were associated with both Lewy body and AD neuropathologic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.